Opus Genetics completes dosing in higher-dose cohort of OPGx-BEST1 gene therapy trial
What happened: On 5 November 2026, Opus Genetics completed dosing in Cohort 2 of BIRD-1, its Phase 1/2 trial of OPGx-BEST1, a one-time gene therapy for inherited retinal diseases caused by faults in the BEST1 gene. The higher-dose cohort treated 11 participants — more than double its original target of five — at 4.5 x 10⁹ vector genomes per eye, three times the dose tested in Cohort 1. Topline three-month data are expected in the first quarter of 2027, and dosing in a potential pivotal Phase 3 trial could begin in the second half of 2027.
Why it matters: BEST1-related diseases, including Best vitelliform macular dystrophy (BVMD) and autosomal recessive bestrophinopathy (ARB), are rare, inherited forms of macular degeneration that progressively destroy central vision, and no approved treatments address their underlying genetic cause. OPGx-BEST1 delivers a working copy of the BEST1 gene to retinal pigment epithelial cells — the cells whose malfunction drives the disease — using a harmless viral carrier (an AAV vector). In the low-dose Cohort 1, reported in September 2026, all five participants showed a clinically meaningful improvement in at least one measure of visual function, with no serious side effects. In August 2026, the company reached agreement with the US Food and Drug Administration (FDA) on a potential pivotal trial endpoint based on measurable improvements in retinal sensitivity combined with a patient-reported outcome.
Read more: Opus Genetics press release, 5 November 2026